Previous 10 | Next 10 |
Gainers: CBAY +73.4% . NVAX +42.9% . YRCW +39.2% . IIVI +21.5% . BHF +13.9% . More news on: CymaBay Therapeutics, Inc., Novavax, Inc., YRC Worldwide Inc., Stocks on the move, , Read more ...
CymaBay Therapeutics (NASDAQ: CBAY ): Q1 GAAP EPS of -$0.19 beats by $0.11 . More news on: CymaBay Therapeutics, Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, , Read more ...
Independent expert panel unanimously concludes there is no clinical, biochemical or histological evidence of seladelpar-induced liver injury in the Phase 2b NASH study Panel unanimously supports re-initiating clinical development of seladelpar pending approval by the FDA Cyma...
NEWARK, Calif., May 04, 2020 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live au...
No shareholder action required at this time CymaBay Therapeutics, Inc. (NASDAQ: CBAY) (the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today confirmed that Engine Capita...
Image source: The Motley Fool. CymaBay Therapeutics Inc (NASDAQ: CBAY) Q4 2019 Earnings Call Mar 12, 2020 , 4:30 p.m. ET Operator Continue reading
IDEAYA Biosciences (NASDAQ: IDYA ) initiated with Buy rating and $12 (192% upside) price target at Roth Capital. More news on: IDEAYA Biosciences, Inc., Menlo Therapeutics Inc., Amarin Corporation plc, Healthcare stocks news, Stocks on the move, , Read more ...
CymaBay Therapeutics, Inc. (CBAY) Q4 2019 Results Earnings Conference Call March 12, 2020, 04:30 PM ET Company Participants Dan Menold - Vice President, Finance Sujal Shah - President and Chief Executive Officer Charles McWherter - Senior Vice President and Chief Scientific Offic...
CymaBay Therapeutics (NASDAQ: CBAY ): Q4 GAAP EPS of -$0.43 misses by $0.04 . More news on: CymaBay Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Investigating unexpected findings from Phase 2b study of seladelpar in NASH In parallel, board and management evaluating all potential strategic alternatives to maximize shareholder value and implementing cost containment efforts Conference call and webcast today at 4:30 p...
News, Short Squeeze, Breakout and More Instantly...
CymaBay Therapeutics Inc. Company Name:
CBAY Stock Symbol:
NASDAQ Market:
CymaBay Therapeutics Inc. Website:
Acquisition Reinforces Gilead’s Leadership in Developing Innovative Therapies For Challenging Liver Diseases Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire CymaBay Therapeutics, Inc. (Nasdaq: CBAY) for appr...
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) is the focus of IBN's latest stock spotlight. The company's shares have moved 0.06% on the day to $32.49. CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chr...
2024-03-12 10:45:01 ET UiPath Inc (PATH) PATH is trading UP for the last 5 days, and it at trading at $24.64 with volume of 4,269,666 and a one day change of $0.54 (2.25%). UiPath Inc has a 52-week low of 12.38 and a 52-week high of $27.87. The business's 50-day moving average price...